Scleroderma News

Explore the details: https://bit.ly/4Aaam5D

Facial changes were a common reason people with systemic sclerosis considered cosmetic therapies, with cost and safety the leading barriers.

Facial changes spur cosmetic therapy interest in systemic sclerosis Facial changes were a common reason people with systemic sclerosis considered cosmetic therapies, with cost and safety the leading barriers.

Get the scoop: https://bit.ly/4j7aJHY

The FDA granted fast track designation to treprostinil, an inhaled therapy to treat Raynaud's phenomenon associated with SSc.

Inhaled therapy for Raynaud's attacks put on FDA fast track The FDA granted fast track designation to treprostinil, an inhaled therapy to treat Raynaud's phenomenon associated with SSc.

Discover more: https://bit.ly/4A8ARZt

Vitamin B3 may reduce abnormalities in the tiny blood vessels of people with scleroderma who have Raynaud’s phenomenon, a study suggests.

Explore the details: https://bit.ly/4y1zeuG

John Stamos will receive the Bob Saget Legacy Award for his longtime support of scleroderma research at an October SRF fundraiser.

Explore the details: https://bit.ly/4xRXcrU

Treatment guidelines for systemic scleroderma (SSc) have evolved with advances in scientific understanding, a study shows.

Get the scoop: https://bit.ly/4g9LXnG

Blood protein KL-6 may help identify people with SSc-ILD at greater risk of short-term lung function decline.

Explore the details: https://bit.ly/4wBdyED

People with SSc who don’t show the scleroderma pattern of small blood vessel damage may have a milder course of the disease, per a study.

Discover more: https://bit.ly/4wrS1y5

A wireless sensor may help track scleroderma-related skin stiffness at home, but larger studies are needed to validate its use.

Discover more: https://bit.ly/45uLd7Q

A new scleroderma survey seeks patient experiences from adults to better understand disease burden, unmet needs, and research priorities.

Explore the details: https://bit.ly/4ice9Zy

Scleroderma was added to the NIH Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases project.